Press Releases

 
Press Releases
  Date Title View
Jan 19, 2016
CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that an updated overall survival analysis of the Phase 3 NAPOLI-1 study of ONIVYDE® (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin achieved a substantial improvement in 12-month overall survival...
Jan 11, 2016
CAMBRIDGE, Mass., Jan. 11, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that an additional overall survival analysis from the Phase 3 NAPOLI-1 study of ONIVYDE™ (irinotecan liposome injection), also known as "nal-IRI," in post-gemcitabine metastatic pancreatic cancer will be presented at the American Soc...
Jan 5, 2016
CAMBRIDGE, Mass., Jan. 5, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President and CEO, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 2:30 p.m. (PT) at the Westin St. Francis Hotel in San Francisco. A live webcast of th...
Dec 22, 2015
CAMBRIDGE, Mass., Dec. 22, 2015 /PR Newswire/ - Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced it filed an amendment to its ongoing Phase 2 clinical study of MM-121 (seribantumab) in patients with heregulin-positive non-small cell lung cancer (NSCLC) with the U.S. Food and Drug Administration (FDA). The amendment includes a change i...
Dec 22, 2015
CAMBRIDGE, Mass., Dec. 22, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced today the closing of a private placement of $175 million in aggregate principal amount of its senior secured notes due 2022 (the "Notes"). The Notes were sold only to qualified institutional buyers within the meaning of Rule 144A under the Secur...
Dec 4, 2015
CAMBRIDGE, Mass., Dec. 4, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present on its innovative nanoliposomal platform for patients with metastatic breast cancer at the 2015 San Antonio Breast Cancer Symposium, December 8 - 12, 2015 at the Henry B. Gonzalez Convention Center in San Antonio, Texas...
Nov 23, 2015
CAMBRIDGE, Mass. and BANNOCKBURN, Ill., Nov. 23, 2015 /PRNewswire/ -- Merrimack (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced that The Lancet has published the article "Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a glo...
Nov 9, 2015
CAMBRIDGE, Mass., Nov. 9, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a biopharmaceutical company that applies systems biology to develop cancer treatments and diagnostics, today announced its third quarter 2015 financial results. Merrimack will host a live conference call and webcast today, Monday, November 9 at 4:30 p.m.,...
Nov 3, 2015
CAMBRIDGE, Mass., Nov. 3, 2015 /PRNewswire/ -- Merrimack (Nasdaq: MACK) today announced that it will present research on several of its therapeutic candidates at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 5-9, 2015 at Hynes Convention Center in Boston. Presentations include recent preclin...
Oct 30, 2015
CAMBRIDGE, Mass., Oct. 30, 2015 /PRNewswire/ -- Merrimack (Nasdaq: MACK) today announced that the company will host its Third Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Monday, November 9.    The call will cover an update on Merrimack's progress as well as a summary of third quarter 2015 financials. A pr...
1
...
NextLast
= add release to Briefcase